HC Wainwright Reiterates Buy Rating for ChromaDex (NASDAQ:CDXC)

HC Wainwright reaffirmed their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.03 EPS. Other analysts have also recently issued research reports […]

Related Keywords

,Millennium Management ,Vanguard Group Inc ,Chromadex Company Profile ,Chromadex Corporation ,Tieton Capital Management ,Blackrock Inc ,Nasdaq ,Free Report ,Get Free Report ,Capital Management ,Street Corp ,Xidex Corporation ,Analytical Reference Standards ,Chromadex Daily ,Chromadex ,Nasdaq Cdxc ,Cdxc ,Medical ,Reiterated Rating ,Hc Wainwright ,